Brainstem lesions may be important in the development of epilepsy in multiple sclerosis patients: An evoked potential study

Clinical Neurophysiology

Volumn 121, Issue 12, 2010, Pages 2104-2110

  Papathanasiou, E S ^a   Pantzaris, M ^a   Myrianthopoulou, P ^a   Kkolou, E ^a   Papacostas, S S ^a  

^a CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

Author keywords

Basal ganglia; Brainstem auditory; Demyelination; Somatosensory; Substantia nigra; Visual

Indexed keywords

CARBAMAZEPINE; CLONAZEPAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ADULT; ARTICLE; BRAIN STEM INJURY; CONTROLLED STUDY; EPILEPSY; EVOKED BRAIN STEM AUDITORY RESPONSE; EVOKED RESPONSE; EVOKED VISUAL RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; SHORT LATENCY SOMATOSENSORY EVOKED POTENTIAL;

ADULT; ANTICONVULSANTS; BRAIN STEM; ELECTROENCEPHALOGRAPHY; EPILEPSY; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; EVOKED POTENTIALS, SOMATOSENSORY; EVOKED POTENTIALS, VISUAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PHYSICAL STIMULATION; RETROSPECTIVE STUDIES; STATISTICS AS TOPIC; UPPER EXTREMITY;

EID: 78049270789     PISSN: 13882457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinph.2010.05.017     Document Type: Article

References (37)

1. Alusi S.H., Aziz T.Z., Glickman S., Jahanshani M., Stein J.F., Bain P.G. Stereotactic lesional surgery for the treatment of tremor in multiple sclerosis. Brain 2001, 124:1576-1589.
2. Borah N.C., Matheshwari M.C. Effect of antiepileptic drugs on short-latency somatosensory evoked potentials. Acta Neurol Scand 1985, 71:331-333.
3. Calabrese M., De Stefano N., Atzori M., Bernardi V., Mattisi I., Barachino L., et al. Extensive cortical inflammation is associated with epilepsy in multiple sclerosis. J Neurol 2008, 255:581-586.
4. Chiappa K.H. Evoked potentials in clinical medicine 1997, Lippincott-Raven publications, Philadelphia. 3rd ed.
5. Clemens B., Ménes A., Nagy Z. Objective assessment of neurotoxicity while shifting from carbazepine to oxcarbazepine. Acta Neurol Scand 2004, 109:324-329.
6. Doretto M.C., Garcia-Cairasco N. Differential audiogenic seizure sensitization by selective unilateral substantia nigra lesions in resistant Wistar rats. Physiol Behav 1995, 58:273-282.
7. Faingold C.L. The role of the brain stem in generalized epileptic seizures. Metab Brain Dis 1987, 2:81-112.
8. Fontoura P., Vale J., Guimarães J. Symptomatic paroxysmal hemidysdonia due to a demyelinated subthalamic lesion. Eur. J. Neurol. 2000, 7:559-562.
9. Fuhr P., Borggrefe-Chappuis A., Schindler C., Kappos L. Visual and motor evoked potentials in the course of multiple sclerosis. Brain 2001, 124:2162-2168.
10. Green J.B., Walcoff M.R., Lucke J.F. Comparison of phenytoin and phenobarbital effects on far-field auditory and somatosensory evoked potential interpeak latencies. Epilepsia 1982, 23:417-421.
11. He Q.P., Smith M.L., Li P.A., Siesjö B.K. Necrosis of the substantia nigra, pars reticulate, in flurothyl-induced status epilepticus is ameliorated by the spin trap alpha phenyl-N-tert-butyl nitrone. Free Radic Biol Med 1997, 22:917-922.
12. Hirsch L.J., Pang T., Claasen J., Chang C., Abou Khaled K., Wittman J., Emerson R.G. Focal motor seizures induced by alerting stimuli in critically ill patients. Epilepsia 2008, 49:698-973.
13. Jung P., Beyerle A., Ziemann U. Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis. Mult Scler 2008, 14:553-556.
14. Kadobayashi I., Nakamura M. Modification of visual, auditory, and somatosensory evoked responses in cortical primary receiving areas by nigral stimulation. Experientia 1974, 30:260-262.
15. Kiernan J.A. The human nervous system: an anatomical viewpoint 2005, Lippincott Williams & Wilkins Press, Baltimore, Maryland. 8th ed.
16. Koch M., Uyttenboogaart M., Polman S., De Keyser J. Seizures in multiple sclerosis. Epilepsia 2008, 49:948-953.
17. Leocani L., Rovaris M., Boneschi F.M., Medaglini S., Rossi P., Martinelli V., et al. Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study. J Neurol Neurosurg Psychiatr 2006, 77:1030-1035.
18. Lundgren J., Ingvar M., Smith M.L., Siesjö B.K. Frontal cortex lesion prior to hyperglycemic ischemia: no decrease in ensuing substantia nigra pars reticulate damage or fatal post-ischemic seizures. Exp Brain Res 1992, 88:355-360.
19. Lünemann J.D., Martin R. Epidemiology and genetics of multiple sclerosis. Neurology and clinical neuroscience 2007, 996-1001. Elsevier, Philadelphia. A.H.V. Schapira (Ed.).
20. Marciani M.G., Spanedda F., Mattia D. Neurophysiologic and neuropsychologic profiles of lamotrigine in epilepsy. Clin Neuropharmacol 1999, 22:159-163.
21. Martinez-Juarez I.E., Lopez-Meza E., Gonzalez-Aragon Mdel C., Ramirez-Bermudez J., Corona T. Epilepsy and multiple sclerosis: increased risk among progressive forms. Epilepsy Res 2009, 84:250-253.
22. Moreau T., Sochurkova D., Lemesle M., Madinier G., Billiar T., Giroud M., et al. Epilepsy in patients with multiple sclerosis: radiological-clinical correlations. Epilepsia 1998, 39:893-896.
23. Panjwani U., Singh S.H., sel Vamurthy W., Gupta H.L., Mukhopadhyay S., Thakur L. Brainstem auditory evoked potentials in epileptics on different anti-epileptic drugs. Indian J Physiol Pharmacol 1996, 40:29-34.
24. Pontes-Neto O.M., Wichert-Ana L., Terra-Bustamante V.C., Velasco T.R., Bustamante G.O., Fernandes R.M., et al. Pontine activation during focal status epilepticus secondary to hamartoma of the floor of the fourth ventricle. Epilepsy Res 2006, 68:265-267.
25. Poser C.M., Brinar V.V. Epilepsy and multiple sclerosis. Epilepsy Behav. 2003, 4:6-12.
26. Rasmussen K., Strecker R.E., Jacobs B.L. Single unit response of adrenergic, serotonergic and dopaminergic neurons in freely moving cats to simple sensory stimuli. Brain Res 1986, 369:336-340.
27. Riley D., Lang A.E. Hemiballism in multiple sclerosis. Mov Dis 1988, 3:88-94.
28. Schmidt-Kastner R., Heim C., Sontag K.H. Damage of substantia nigra pars reticulate during pilocarpine-induced status epilepticus in the rat: immunohistochemical study of neurons, astrocytes and serum-protein extravasation. Exp Brain Res 1991, 86:125-140.
29. Sokić D.V., Stojsavjević N., Drulović J., Dujmović I., Mesaroš S., Ercegovac M., et al. Seizures in multiple sclerosis. Epilepsia 2001, 42:72-79.
30. Spatt J., Chaix R., Mamoli B. Epileptic and non-epileptic seizures in multiple sclerosis. J Neurol 2001, 248:2-9.
31. Striano P., Orefice G., Brescia Morra V., Boccella P., Sarappa C., Lanzillo R., et al. Epileptic seizures in multiple sclerosis: clinical and EEG correlations. Neurol Sci 2003, 24:322-328.
32. Tao G., Datta S., He R., Nelson F., Wolinsky J.S., Narayana P.A. Deep gray matter atrophy in multiple sclerosis: a tensor based morphometry. J Neurol Sci 2009, 282:39-46.
33. Thompson A.J., Kermode A.G., MacManus D.G., Kendall B.E., Kingsley D.P., Moseley I.F., McDonald W.I. Patterns of disease activity in multiple sclerosis: a clinical and magnetic resonance imaging study. BMJ 1990, 300:631-634.
34. Thompson A.J., Kermode A.G., Moseley I.F., MacManus D.G., McDonald W.I. Seizures due to multiple sclerosis: seven patients with MRI correlations. J Neurol Neurosurg Psychiatr 1993, 56:1317-1320.
35. Truyen L., Barkhof F., Frequin S.T., Polman C.H., Tobi H., Hommes O.R., et al. Magnetic resonance imaging of epilepsy in multiple sclerosis: a case control study. Implications for treatment trials with 4-aminopyridine. Mult Scler 1996, 1:213-217.
36. Vercellino M., Masera S., Lorenzatti M., Condello C., Merola A., Mattioda A., et al. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol 2009, 68:489-502.
37. Verrotti A., Trotta D., Cutarella R., Pascarella R., Morgese G., Chiarelli F. Effects of antiepileptic drugs on evoked potentials in epileptic children. Pediatr Neurol 2000, 23:397-402.